Jason Harris

June 23, 2021

The survival benefit obtained with Ibrance plus Faslodex persisted over a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

June 07, 2021

Twice-daily treatment with Qinlock following disease progression after treatment with fourth-line therapy in patients with advanced gastrointestinal stromal tumor was associated with extended survival outcomes.

October 07, 2019

Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.

September 12, 2019

The Pink Luminous Advocacy Project has introduced the Breast Awareness app, the first multilingual, unisex breast self-examination application.

October 02, 2018

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

July 15, 2018

Investigators are learning how to take a tumor biopsy from a patient, grow small tumors called organoids in the lab, and test cancer treatments on them to see which work best.

July 15, 2018

The first thing a woman should do after receiving a diagnosis of ovarian cancer, according to Teresa P. Díaz-Montes, M.D., M.P.H., is nothing. At least not right away.

May 07, 2018

A higher complete response rate was seen in patients given both agents compared with those given Imbruvica alone.

March 20, 2018

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

March 19, 2018

The combination induced a 31 percent disease control rate (DCR) in patients with heavily-pretreated metastatic colorectal cancer (mCRC).

March 13, 2018

Keytruda (pembrolizumab) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of patients with advanced cervical cancer with disease progression or after chemotherapy.

February 13, 2018

Lorlatinib was granted a priority review to a new drug application (NDA) for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinases inhibitors (TKIs).

December 11, 2017

Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat adult and pediatric patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).

December 09, 2017

The incidence of human papillomavirus-related oropharyngeal cancer (HPV-OPC) is on the rise. Researchers at Johns Hopkins University assessed survey data to determine whether the risk among the general population is rising as well. Results show that for most people, the risk remains low.

December 07, 2017

A reveiw of five clinical trial findings suggests that gonadotropin-releasing hormone analog has the potential to preserve ovarian function and fertility in premenopausal breast cancer patients.

December 07, 2017

New research demonstrates that a CDK4/6 inhibitor, used in combination with standard endocrine therapy with temporary ovarian suppression significantly improves progression-free survival in younger patients who currently have few treatment options.

December 05, 2017

Longer time in between pre- and postoperative chemotherapy may be associated with significantly worse survival outcomes in women with ovarian cancer.

November 15, 2017

November 03, 2017

A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.

October 30, 2017

If approved, the new indication would make frontline Avastin available in combination with carboplatin and paclitaxel, followed by Avastin alone, for women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The FDA is expected to render a decision on the sBLA by June 25, 2018.

October 25, 2017

Once weekly Kyprolis (carfilzomib) had better efficacy than lower-doses of the drug given twice a week to treat patients with relapsed/refractory multiple myeloma, according to results from the phase 3 ARROW trial.

October 23, 2017

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the adjuvant treatment of patients who have stage 3 melanoma and a BRAF V600 mutation, after they have already had a complete resection.

October 18, 2017

Opdivo (nivolumab) was granted a priority review to a supplemental biologics license application (sBLA) to treat patients with melanoma who have a high risk of disease recurrence after complete surgical resection, according to Bristol-Myers Squibb (BMS), the company that makes the drug.

October 17, 2017

Overall survival (OS) was improved when patients with advanced liver cancer took Cabometyx (cabozantinib), compared to those who were given placebo. All participants previously took Nexavar (sorafenib).

October 09, 2017

Tagrisso (osimertinib) was granted a Breakthrough Therapy Designation for the firstline treatment of patients who have metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).

October 02, 2017

Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma

September 18, 2017

Jevtana (cabazitaxel) was granted approval by the Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen.

September 14, 2017

The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.

September 08, 2017

According to the results of a recent study conducted in China, patients with stage 3B/4 non-small cell lung cancer (NSCLC) saw a 3.3-month increase in median progression-free survival (PFS) when taking Conmana (icotinib) compared to those who were taking chemotherapy.

September 06, 2017

The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.